Are any Ingevity (NGVT) shares in the Form 4 related to an employee stock purchase plan?

The filing explains that the total holdings include shares acquired under Ingevity’s Employee Stock Purchase Plan. These ESPP shares were bought at 85% of the stock’s closing price on specified 2025 dates, but they are context for ownership, not part of the February 2026 grants.

Did the Ingevity (NGVT) Form 4 show any share sales or tax withholdings?

The footnotes state that some shares were withheld by Ingevity to cover tax obligations tied to vesting PSUs. However, the structured transaction data provided here only shows grant or award acquisitions, with no open-market sales reported.

Ingevity (NGVT) SVP Richard White receives 1,634-share stock award

Q: Was the Ingevity (NGVT) Form 4 transaction a purchase or a compensation award?

The Form 4 reflects grant or award acquisitions , not open-market purchases. Both entries use transaction code “A,” indicating equity compensation, including settlement of performance-based restricted stock units into common shares.

Q: How many Ingevity (NGVT) shares did Richard Allen White Jr. acquire in this Form 4?

He acquired a total of 1,634 shares of Ingevity common stock, consisting of 1,204 shares at $0 per share and 430 shares at $70.52 per share, all classified as grant or award acquisitions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ingevity Corp senior executive Richard Allen White Jr., SVP and President of Performance Chemicals, reported stock-based compensation awards of common stock. On February 26, 2026, he acquired 1,204 shares at $0 per share and 430 shares at $70.52 per share as grant or award transactions. Footnotes explain that performance-based restricted stock units were certified and settled in common shares rather than cash.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider White Richard Allen JR

Role SVP and Pres, Perf Chemicals

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,204	$0.00	--
Grant/Award	Common Stock	430	$70.52	$30K

Holdings After Transaction: Common Stock — 22,450 shares (Direct)

Footnotes (1)

The Talent and Compensation Committee of the Company's board of directors certified the attainment of performance goals for certain performance-based restricted stock awards ("PSUs") effective February 26, 2026. The PSUs were settled with shares of common stock. Includes (i) 94 shares of Common Stock purchased pursuant to the Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan, as amended ("ESPP") for the purchase period of July 1, 2025 to September 30, 2025 (the "September ESPP Shares"), and (ii) 76 shares of Common Stock purchased pursuant to the ESPP for the purchase period of October 1, 2025 to December 31, 2025 (the "December ESPP Shares"). In accordance with the terms of the ESPP, the September ESPP Shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on July 1, 2025 and the December ESPP Shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on October 1, 2025. Shares withheld by the Company to satisfy tax withholding obligations related to the PSUs that vested on February 26, 2026.

Form 4 Insider Transactions: What Each Field Means →

03/02/2026 - 04:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Richard Allen JR

(Last)

(First)

(Middle)

C/O INGEVITY CORPORATION

4920 O'HEAR AVE, SUITE 400

(Street)

NORTH CHARLESTON

29405

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP and Pres, Perf Chemicals

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/26/2026		A		1,204⁽¹⁾	A	$0	22,450⁽²⁾	D
Common Stock	02/26/2026		A		430⁽³⁾	D	$70.52	22,020	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Talent and Compensation Committee of the Company's board of directors certified the attainment of performance goals for certain performance-based restricted stock awards ("PSUs") effective February 26, 2026. The PSUs were settled with shares of common stock.

2. Includes (i) 94 shares of Common Stock purchased pursuant to the Amended and Restated 2017 Ingevity Corporation Employee Stock Purchase Plan, as amended ("ESPP") for the purchase period of July 1, 2025 to September 30, 2025 (the "September ESPP Shares"), and (ii) 76 shares of Common Stock purchased pursuant to the ESPP for the purchase period of October 1, 2025 to December 31, 2025 (the "December ESPP Shares"). In accordance with the terms of the ESPP, the September ESPP Shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on July 1, 2025 and the December ESPP Shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on October 1, 2025.

3. Shares withheld by the Company to satisfy tax withholding obligations related to the PSUs that vested on February 26, 2026.

Remarks:

	Richard Allen White Jr. By: Mavis Huger as Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ingevity (NGVT) executive Richard Allen White Jr. report?

Richard Allen White Jr. reported acquiring common stock through equity awards. On February 26, 2026, he received 1,204 shares at $0 and 430 shares at $70.52 per share as stock-based compensation grants and settlements.

Was the Ingevity (NGVT) Form 4 transaction a purchase or a compensation award?

The Form 4 reflects grant or award acquisitions, not open-market purchases. Both entries use transaction code “A,” indicating equity compensation, including settlement of performance-based restricted stock units into common shares.

How many Ingevity (NGVT) shares did Richard Allen White Jr. acquire in this Form 4?

He acquired a total of 1,634 shares of Ingevity common stock, consisting of 1,204 shares at $0 per share and 430 shares at $70.52 per share, all classified as grant or award acquisitions.

What do the performance-based restricted stock units (PSUs) mean for Ingevity (NGVT) executive compensation?

The filing notes that the Talent and Compensation Committee certified performance goals for PSUs. These performance-based restricted stock units were then settled in Ingevity common shares, directly tying a portion of the executive’s compensation to performance outcomes.